ArticleFrontiers in oncology2026
Durable response to sotorasib-based combination therapy in advanced lung adenocarcinoma harboring KRAS G12C and STK11 mutations: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma is a prevalent and aggressive subtype of non-small cell lung cancer (NSCLC). Mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) represent key oncogenic drivers and are associated with poor prognosis. Sotorasib is a KRAS G12C inhibitor. It suppresses tumor growth by specifically and irreversibly locking the mutant KRAS protein. Currently, sotorasib is only approved for later-line treatment of KRAS G12C-mutated NSCLC. Here, we present a case of advanced NSCLC harboring a KRAS G12C and STK11 mutations. The patient received an exploratory first-line therapy with sotorasib combined with immunotherapy and chemotherapy, achieving significant and durable clinical benefit lasting 23 months, with manageable adverse events. This case highlights the potential of sotorasib in combination regimens as a first-line treatment strategy for KRAS G12C-mutated NSCLC and underscores the importance of individualized treatment planning. However, the use of sotorasib in the first-line setting remains an exploratory off-label approach and requires further clinical evidence to validate this treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.